Program

HomeProgram ▶ Program at a Glance
Program at a Glance

 

Here is a brief guide into the robust offerings you will find at ATS 2020 Virtual to help you make the most out of your virtual experience. Each day, we will launch and offer key sessions pertaining to specific topics.

All clinical & scientific sessions, a select number of virtual industry programs, virtual exhibit hall, and ePosters will continue to be available on-demand through Nov. 10 (A few industry programs will be available live only, at the date and time stated below).




Aug. 5

Scientific sessions include:

  • A1- Clinical Year in Review 1
  • A81- Nursing Year in Review: Complementary Health Approaches for Patient-Reported Symptoms in Pulmonary, Critical Care, and Sleep Medicine
  • B1- Clinical Year in Review 2
  • B81- Pediatric Year in Review
  • C1- Clinical Year in Review 3
  • D1- Clinical Year in Review 4
  • Global Review of COVID-19 (Part 1)

Industry programming includes sessions from:

  • Sanofi Genzyme and Regeneron on asthma
    Live, 1-2 p.m. (on-demand after live)
  • Gilead Sciences & Galapagos on IPF
    1-1:30 p.m.
  • Regeneron and Sanofi Genzyme on asthma
    Live, 5:30-6:30 p.m.(on-demand after live)
  • Boehringer Ingelheim Pharmaceuticals, Inc. on ILD
    Live, 5:30-6:30 p.m. (on-demand after live)

Daily



comments.png

Live Expert Chat sessions let you chat with an expert and ask questions on what you’ve learned for the day.




eposters

The Poster Hall highlights abstracts showcasing the latest scientific advances and discoveries.




virtual exhibits

Our Exhibit Hall showcases more than 50 industry leaders, promoting the latest products and services to improve patient care.




virtual exhibits

Up for a challenge? Try the Virtual Quest trivia game for a chance to win prizes!




networking

ATS 2020 Virtual offers a variety of networking opportunities for attendees!




briefcase-fa-2020.png

How Do I Attend ATS 2020?

Is this your first virtual conference? Click here for a simple guide to ATS 2020 Virtual!

Aug. 6

Scientific sessions include:

  • A83- Great Cases: Clinical, Radiologic, and Pathologic Correlations by Master Physicians
  • B2- When CF Becomes Non-CF Bronchiectasis: The Ongoing Battle Against Infection in Cystic Fibrosis During the CFTR-Modulator Era
  • B9- 2020 Vision of TB
  • B89- Unlocking the Potential of Trained Immunity to Treat Respiratory Infection and Inflammation
  • C3- Pediatric Clinical Chest Rounds
  • D86- Cutting-Edge Diagnostics: Integrating Multi-Omic Platforms in the Diagnosis of Lung Infections
  • D89- Novel Therapeutic Management in Non-Tuberculous Mycobacteria

Industry programming includes sessions from:

  • GlaxoSmithKline (GSK) on COPD
    Live, 1-2 p.m. (not available on-demand)
  • AstraZeneca on asthma
    1-2 p.m.
  • Sanofi Genzyme and Regeneron on asthma
    Live, 5:30-6:30 p.m. (on-demand after live)
  • Acceleron Pharma on PAH
    5:30-6 p.m. (on-demand after live)

Aug. 7

Scientific sessions include:

  • A5- Lung Regeneration: What Do We Want?
  • A85- Lung Regeneration: How Do We Get There?
  • B5- Cellular Plasticity and Lung Tissue Bioengineering: Novel Approaches to Advanced Respiratory Disease
  • B8- Inflammation in ARDS: Too Much or Too Little?
  • C7- Deciphering the Alveolar Puzzle: Cells in the Distal Lung During Injury and Aging
  • C85- Scientific Breakthroughs: New Views of Tissue Regeneration
  • D8- The Matrix Revealed: Understanding Extracellular Matrix Influences on Lung Diseases

Industry programming includes sessions from:

  • GlaxoSmithKline (GSK) on asthma
    Live, 1-2 p.m. (not available on-demand)
  • Mallinckrodt Pharmaceuticals on sarcoidosis
    Live, 1-1:30 p.m. (not available on-demand)
  • Biodesix on lung cancer/lung disease
    Live, 5:30-6 p.m. (on-demand after live)
  • Philips on COVID-19
    5:30-6 p.m.

Aug. 8

Scientific sessions include:

  • A4- The New Era of Critical Care for Cancer Patients: Cells to Systems
  • A12- Palliative Care in Chronic Respiratory Disease: A State of the Science
  • B6- Advancing Care Quality for Adult Home Oxygen Patients
  • B13- Clinical Practice 2020: Effectively Learning, Teaching, and Sharing Medical Information
  • B86- Delivery of Pulmonary Rehabilitation in the Face of Social and Health Inequality: Can We Bridge the Gap?
  • C10- Building Global Advocacy to Advance Global Lung Health
  • D4- Redefining Time Zero: Critical Care Delivery in the Field, ED, and Ward

Industry programming includes sessions from:

  • GlaxoSmithKline (GSK) on COPD
    Live, 1-2 p.m. (not available on-demand)
  • Mallinckrodt Pharmaceuticals on sarcoidosis
    Live, 1-1:30 p.m. (not available on-demand)
  • Genentech, a Member of the Roche Group on IPF
    Live, 5:30-6 p.m. (not available on-demand)
  • Vindico Medical Education, supported by Insmed Incorporated on NTM
    Live, 5:30-6:30 p.m. (on-demand after live).

Aug. 9

Scientific sessions include:

  • B11- Beyond DNA: The Unseen Genome and Novel Omics Approaches to Pulmonary Hypertension
  • B87- Sleep Clinic 2030: Big Data, Wearables and Deep Learning Change Sleep Medicine
  • C86- ATS Mythbusters: Novel Single Cell Profiling Technologies Will Have a Significant Impact on the Understanding and Management of Pulmonary Fibrosis
  • C91- Integrative Genomics Strategies for Complex Respiratory Diseases

Industry programming includes sessions from:

  • Genentech, a Member of the Roche Group on IPF
    Live, 1-2 p.m. (not available on-demand)
  • Jazz Pharmaceuticals on obstructive sleep apnea
    Live, 1-1:30 p.m. (on-demand after live)
  • Amgen/AstraZeneca on asthma
    5:30-6 p.m. (on-demand after live)
  • Vindico Medical Education, supported by Boehringer Ingelheim Pharmaceuticals, Inc. on PF-ILD
    5:30-6:30 p.m. (on-demand after live)

Aug. 10

Scientific sessions include:

  • A3- Early COPD: Getting to the Root of the Problem
  • A90- Emerging Dangers From E-Cigarettes: Let's Have a Vape Debate
  • B7- Lung Cancer Screening: Something Old, Something New, Something Borrowed, Something Blue
  • B83- Early Detection and Diagnosis of Idiopathic Pulmonary Fibrosis
  • C11- Evolving Knowledge of the Effect of Cannabis and Cannabinoids on the Lung
  • D10- The Evolution of Inhalation: The Biologic, Physical, and Policy Implications of Vaping and Other Novel Devices
  • D85- Environmental Exposures and the Airway Microbiome
  • Global Review of COVID-19 (Part 2)